PA8614301A1 - Derivados de tropano - Google Patents
Derivados de tropanoInfo
- Publication number
- PA8614301A1 PA8614301A1 PA20048614301A PA8614301A PA8614301A1 PA 8614301 A1 PA8614301 A1 PA 8614301A1 PA 20048614301 A PA20048614301 A PA 20048614301A PA 8614301 A PA8614301 A PA 8614301A PA 8614301 A1 PA8614301 A1 PA 8614301A1
- Authority
- PA
- Panama
- Prior art keywords
- treatment
- tropano
- derivatives
- ccr5
- chemiokines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
LA PRESENTE INVENCION PROPORCIONA COMPUESTO DE FORMULA (I) EN LA QUE R1 Y R2 SON COMO SE DEFINEN ANTERIORMENTE EN LA PRESENTE MEMORIA. LOS COMPUESTOS DE LA PRESENTE INVENCION SON MODULADORES, ESPECIALMENTE ANTAGONISTAS, DE LA ACTIVIDAD DE RECEPTORES CCR5 DE QUIMIOQUINAS. LOS MODULARES DE RECEPTOR CCR5 PUEDEN SER UTILES EN EL TRATAMIENTO DE DIVERSAS ENFERMEDADES Y AFECCIONES INFLAMATORIAS Y EN EL TRATAMIENTO DE INFECCION POR VIH Y RETROVIRUS GENETICAMENTE RELACIONADOS.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0323236.0A GB0323236D0 (en) | 2003-10-03 | 2003-10-03 | Chemical compounds |
GB0325020A GB0325020D0 (en) | 2003-10-27 | 2003-10-27 | Chemical compounds |
GB0418566A GB0418566D0 (en) | 2004-08-19 | 2004-08-19 | Tropane derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8614301A1 true PA8614301A1 (es) | 2005-05-10 |
Family
ID=34426592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20048614301A PA8614301A1 (es) | 2003-10-03 | 2004-10-01 | Derivados de tropano |
Country Status (35)
Country | Link |
---|---|
US (2) | US7309790B2 (es) |
EP (1) | EP1682545B1 (es) |
JP (1) | JP4874107B2 (es) |
KR (1) | KR100777885B1 (es) |
AP (1) | AP2174A (es) |
AR (1) | AR045856A1 (es) |
AT (1) | ATE380813T1 (es) |
AU (1) | AU2004278158B2 (es) |
BR (1) | BRPI0414862A (es) |
CA (1) | CA2540834C (es) |
CY (1) | CY1107281T1 (es) |
DE (1) | DE602004010708T2 (es) |
DK (1) | DK1682545T3 (es) |
EA (1) | EA009941B1 (es) |
EC (1) | ECSP066475A (es) |
ES (1) | ES2295924T3 (es) |
GE (1) | GEP20084417B (es) |
HN (1) | HN2004000383A (es) |
HR (1) | HRP20080052T3 (es) |
IL (1) | IL174208A0 (es) |
MA (1) | MA28080A1 (es) |
MX (1) | MXPA06003749A (es) |
MY (1) | MY137609A (es) |
NO (1) | NO20061978L (es) |
NZ (1) | NZ545837A (es) |
OA (1) | OA13266A (es) |
PA (1) | PA8614301A1 (es) |
PE (1) | PE20050961A1 (es) |
PL (1) | PL1682545T3 (es) |
PT (1) | PT1682545E (es) |
RS (1) | RS20060198A (es) |
SI (1) | SI1682545T1 (es) |
TW (1) | TWI280244B (es) |
UY (1) | UY28546A1 (es) |
WO (1) | WO2005033107A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
PL1656372T3 (pl) | 2003-07-30 | 2013-08-30 | Rigel Pharmaceuticals Inc | Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym |
CN105348203B (zh) | 2005-06-08 | 2018-09-18 | 里格尔药品股份有限公司 | 抑制jak途径的组合物和方法 |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
JP2009528295A (ja) | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Jak経路の阻害のための組成物および方法 |
MX2008012936A (es) * | 2006-04-05 | 2008-10-15 | Schering Corp | Formulaciones farmaceuticas: sales de 8-[{1-(3,5-bis-(trifluoromet il)fenil)-etoxi} metil]-8-fenil-1,7-diaza-espiro[4,5]decan-2-ona y metodos de tratamiento usando las mismas. |
US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
DK2089369T3 (da) | 2006-10-19 | 2011-05-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme |
EP2120938A4 (en) * | 2006-12-20 | 2010-12-08 | Merck Sharp & Dohme | IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES |
AR065802A1 (es) * | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
MX2010004493A (es) * | 2007-10-25 | 2010-06-11 | Exelixis Inc | Compuestos de tropano. |
PT2265607T (pt) | 2008-02-15 | 2017-03-08 | Rigel Pharmaceuticals Inc | Compostos de pirimidina-2-amina e sua utilização como inibidores de jak cinases |
AU2009244897B2 (en) | 2008-04-16 | 2014-11-13 | Alexion Pharmaceuticals, Inc. | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
AU2009238590A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
JP2010043063A (ja) | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
ES2609640T3 (es) | 2009-08-14 | 2017-04-21 | Opko Health, Inc | Formulaciones intravenosas de rolapitant |
BR112012024522A2 (pt) | 2010-04-02 | 2017-08-08 | Phivco 1 Llc | combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio |
WO2012061428A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
EP2782579B1 (en) | 2011-11-23 | 2019-01-02 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
PL3049378T3 (pl) * | 2013-09-25 | 2019-06-28 | SpecGx LLC | Wytwarzanie radiojodowanego 3-fluoropropylo-nor-beta-CIT |
GB201321748D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
WO2023192360A1 (en) * | 2022-03-31 | 2023-10-05 | Incelldx, Inc. | Methods of treating a subject for post-treatment lyme disease (ptld) and compositions for use in the same |
WO2023192361A1 (en) * | 2022-03-31 | 2023-10-05 | Incelldx, Inc. | Methods of treating a subject for fibromyalgia and compositions for use in the same |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
UA49801C2 (uk) | 1994-04-19 | 2002-10-15 | Нейросерч А/С | Похідні тропан-2-альдоксиму, спосіб їх отримання, фармацевтична композиція, спосіб лікування |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
AU720358B2 (en) | 1996-02-22 | 2000-06-01 | Neurosearch A/S | Tropane-derivatives, their preparation and use |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
SI1284974T1 (en) * | 2000-05-26 | 2004-08-31 | Pfizer Inc. | Triazolyl tropane derivatives as ccr5 modulators |
US6855724B2 (en) * | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
RS51550B (en) | 2002-04-08 | 2011-06-30 | Pfizer Inc. | KAO DERIVATIVES KAO MODULATORS CCR5 |
-
2004
- 2004-09-28 BR BRPI0414862-2A patent/BRPI0414862A/pt not_active IP Right Cessation
- 2004-09-28 GE GEAP20049330A patent/GEP20084417B/en unknown
- 2004-09-28 JP JP2006530737A patent/JP4874107B2/ja not_active Expired - Fee Related
- 2004-09-28 DK DK04769496T patent/DK1682545T3/da active
- 2004-09-28 PT PT04769496T patent/PT1682545E/pt unknown
- 2004-09-28 PL PL04769496T patent/PL1682545T3/pl unknown
- 2004-09-28 MX MXPA06003749A patent/MXPA06003749A/es active IP Right Grant
- 2004-09-28 AP AP2006003580A patent/AP2174A/xx active
- 2004-09-28 ES ES04769496T patent/ES2295924T3/es active Active
- 2004-09-28 RS YUP-2006/0198A patent/RS20060198A/sr unknown
- 2004-09-28 NZ NZ545837A patent/NZ545837A/en not_active IP Right Cessation
- 2004-09-28 AT AT04769496T patent/ATE380813T1/de active
- 2004-09-28 KR KR1020067006293A patent/KR100777885B1/ko not_active IP Right Cessation
- 2004-09-28 OA OA1200600114A patent/OA13266A/en unknown
- 2004-09-28 CA CA2540834A patent/CA2540834C/en not_active Expired - Fee Related
- 2004-09-28 AU AU2004278158A patent/AU2004278158B2/en not_active Ceased
- 2004-09-28 EP EP04769496A patent/EP1682545B1/en active Active
- 2004-09-28 DE DE602004010708T patent/DE602004010708T2/de active Active
- 2004-09-28 SI SI200430564T patent/SI1682545T1/sl unknown
- 2004-09-28 US US10/953,136 patent/US7309790B2/en not_active Expired - Fee Related
- 2004-09-28 EA EA200600480A patent/EA009941B1/ru not_active IP Right Cessation
- 2004-09-28 WO PCT/IB2004/003153 patent/WO2005033107A1/en active IP Right Grant
- 2004-09-29 HN HN2004000383A patent/HN2004000383A/es unknown
- 2004-09-29 TW TW093129475A patent/TWI280244B/zh not_active IP Right Cessation
- 2004-10-01 PE PE2004000965A patent/PE20050961A1/es not_active Application Discontinuation
- 2004-10-01 UY UY28546A patent/UY28546A1/es unknown
- 2004-10-01 MY MYPI20044043A patent/MY137609A/en unknown
- 2004-10-01 AR ARP040103581A patent/AR045856A1/es not_active Application Discontinuation
- 2004-10-01 PA PA20048614301A patent/PA8614301A1/es unknown
-
2006
- 2006-03-09 IL IL174208A patent/IL174208A0/en unknown
- 2006-04-03 EC EC2006006475A patent/ECSP066475A/es unknown
- 2006-04-03 MA MA28906A patent/MA28080A1/fr unknown
- 2006-05-03 NO NO20061978A patent/NO20061978L/no not_active Application Discontinuation
-
2007
- 2007-08-27 US US11/845,500 patent/US7790740B2/en not_active Expired - Fee Related
-
2008
- 2008-01-30 HR HR20080052T patent/HRP20080052T3/xx unknown
- 2008-02-14 CY CY20081100178T patent/CY1107281T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8614301A1 (es) | Derivados de tropano | |
NI200300053A (es) | Derivados del tropano utiles en terapia. | |
ECSP067121A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
CR8775A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
CR8745A (es) | 3-(4-heteroarilciclohexilmino)ciclopentacarboxamidas como moduladores de receptores de quimiocinas | |
CR10060A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
UY28906A1 (es) | Derivados de pirimidina que son antagonistas del receptor vitronectina | |
ECSP088863A (es) | Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia | |
SV2007002007A (es) | Compuestos de quinolina sustituidos ref. pc 25932a | |
ECSP066549A (es) | Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos | |
SV2006002110A (es) | Compuestos terapeuticos ref. pc32293a | |
UY29412A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos. | |
ECSP088966A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
UY29197A1 (es) | Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos | |
ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
CR20110381A (es) | Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 | |
UY29134A1 (es) | Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones | |
UY30706A1 (es) | Diaril, dipiridinil y arilpiridinil derivados y usos de los mismos | |
UY30363A1 (es) | Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones | |
GT200700075A (es) | Derivados de eter diarilico y usos de los mismos | |
ECSP088968A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
CR8323A (es) | Derivados de tropano | |
ECSP045344A (es) | Derivados del tropano utiles en terapia | |
DOP2004001002A (es) | Derivados de 2-metil-4,5,6,7-tetrahidro-1h-imidazo[4,5,c]-piridin-1-il-8-azabiclo-[3.2.1]-octo-8-il]-1-(3-fluorofenil) propil con actividad antagonista del receptor ccr5 | |
UY29043A1 (es) | Derivados de diarilmetil piperazina, preparaciones de los mismos y usos de los mismos |